Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on February 13, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 13, 2026 TAIKO PHARMACEUTICAL CO.,LTD. [4574.T] TOKYO, Feb 13 (Pulse News Wire) -- Taiko Pharmaceutical Co., Ltd. (4574.T), represented by President and CEO Takeshi Shibata, announced today that its board of directors has resolved to propose amendments to certain articles of the company's articles of incorporation at the upcoming 80th ordinary shareholders' meeting scheduled for March 27, 2026. The proposed changes aim to address potential situations wher